Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.72 | — | — | 6.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.42 | 4.00 | 4.22 | 5.18 | 6.36 | 5.25 | 5.05 | 3.51 | 3.99 | 7.33 | 4.38 | 1.56 | 2.26 | 1.37 | 1.53 | 0.86 | 0.85 | 1.66 | 2.61 | 1.96 | 4.41 |
| — | -23.8% | -16.5% | +47.6% | +59.5% | -28.4% | +15.4% | +124.4% | +76.2% | +433.9% | +185.1% | +81.7% | +167.4% | -17.2% | -41.2% | -56.2% | -80.8% | -55.7% | +1.3% | -21.4% | +30.6% | |
| P/B Ratio | 0.67 | 0.60 | 0.64 | 1.16 | 1.24 | 1.08 | 0.90 | 1.39 | 1.47 | 1.29 | 1.38 | 1.08 | — | — | — | — | — | — | 12.51 | 3.18 | 5.06 |
| — | -44.6% | -29.2% | -16.4% | -15.1% | -16.7% | -34.9% | +28.7% | — | — | — | — | — | — | — | — | — | — | +355.3% | -0.9% | +42.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.9% | 52.4% | 53.5% | 43.0% | 48.5% | 48.8% | 54.6% | 46.9% | 51.7% | 46.1% | 53.1% | 47.4% | 44.0% | 49.2% | 48.9% | 41.3% | 36.0% | 23.6% | 46.2% | 52.9% | 48.0% |
| — | +7.3% | -2.1% | -8.2% | -6.2% | +5.9% | +2.9% | -1.1% | +17.6% | -6.2% | +8.6% | +14.7% | +22.3% | +108.5% | +5.9% | -21.9% | -25.0% | -55.5% | -20.5% | -10.0% | -24.5% | |
| Operating Margin | -109.3% | -126.3% | -44.5% | -92.1% | -120.0% | -108.9% | -119.7% | -70.2% | -70.5% | -134.5% | -132.2% | -75.9% | -83.5% | -63.1% | -66.1% | -78.1% | -113.2% | -205.4% | -103.8% | -29.4% | -68.8% |
| — | -16.0% | +62.8% | -31.2% | -70.2% | +19.1% | +9.4% | +7.4% | +15.5% | -113.3% | -100.1% | +2.9% | +26.3% | +69.3% | +36.3% | -165.5% | -64.5% | -268.9% | -76.1% | +22.4% | -401.9% | |
| Net Margin | -87.8% | -133.1% | -213.9% | 81.0% | -177.4% | -153.7% | -128.7% | -72.9% | -59.9% | -203.3% | -70.6% | -70.2% | -82.8% | -61.6% | -67.1% | -77.1% | -114.7% | -338.4% | -287.8% | -24.6% | -48.6% |
| — | +13.4% | -66.1% | +211.1% | -196.2% | +24.4% | -82.3% | -4.0% | +27.6% | -230.0% | -5.3% | +9.1% | +27.9% | +81.8% | +76.7% | -213.1% | -136.3% | -512.3% | -401.5% | +39.0% | -222.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.7% | -4.9% | -9.2% | 4.7% | -8.4% | -7.6% | -5.6% | -7.1% | -5.4% | -8.4% | -8.7% | -125.6% | — | — | — | — | — | — | -130.7% | -9.7% | -13.3% |
| — | +36.1% | -63.3% | +166.0% | -56.2% | +9.5% | +35.3% | +94.4% | — | — | — | — | — | — | — | — | — | — | -809.9% | +21.5% | -214.6% | |
| ROA | -12.7% | -4.2% | -7.5% | 3.5% | -6.3% | -5.9% | -4.4% | -5.3% | -3.9% | -6.2% | -5.8% | -6.0% | -6.0% | -4.7% | -4.4% | -5.2% | -6.9% | -17.8% | -27.9% | -3.4% | -4.8% |
| — | +28.2% | -71.6% | +166.1% | -63.3% | +4.3% | +25.2% | +11.8% | +35.9% | -31.3% | -32.2% | -15.3% | +12.1% | +73.7% | +84.1% | -53.0% | -41.9% | -209.0% | -366.7% | +39.2% | -144.4% | |
| ROIC | -20.7% | -6.1% | -2.1% | -5.2% | -5.9% | -5.6% | -5.4% | -7.0% | -6.8% | -6.4% | -15.3% | -32.7% | — | — | — | — | — | -46.7% | -13.3% | -4.8% | -8.4% |
| — | -8.3% | +60.4% | +25.7% | +12.6% | +11.3% | +64.6% | +78.7% | — | — | — | — | — | — | — | — | — | -516.6% | -53.1% | +35.7% | -269.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.05 | 0.05 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.18 | 0.18 | 0.16 | 0.60 | — | — | — | — | — | — | 6.33 | 1.18 | 1.06 |
| — | -22.8% | -24.2% | +3.9% | -62.5% | -62.0% | -56.4% | -88.4% | — | — | — | — | — | — | — | — | — | — | +725.6% | +72.1% | +68.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.19 | 9.10 | 12.36 | 4.19 | 4.38 | 5.16 | 6.12 | 5.70 | 3.76 | 3.88 | 4.50 | 1.45 | 3.30 | 3.91 | 4.45 | 4.81 | 4.96 | 5.87 | 1.55 | 1.45 | 1.55 |
| — | +76.3% | +102.0% | -26.5% | +16.4% | +33.1% | +35.8% | +294.2% | +14.1% | -0.8% | +1.2% | -69.9% | -33.6% | -33.4% | +186.9% | +230.6% | +219.3% | +296.4% | -13.8% | -33.0% | -45.8% | |
| Quick Ratio | 4.01 | 8.80 | 11.92 | 4.01 | 4.14 | 4.92 | 5.37 | 5.09 | 3.41 | 3.53 | 4.17 | 1.26 | 2.87 | 3.44 | 3.94 | 4.31 | 4.49 | 5.33 | 1.06 | 1.03 | 1.04 |
| — | +79.0% | +122.0% | -21.2% | +21.5% | +39.1% | +28.7% | +303.9% | +18.6% | +2.8% | +6.0% | -70.8% | -35.9% | -35.6% | +271.9% | +317.2% | +333.1% | +430.4% | -23.8% | -42.8% | -57.0% | |
| Interest Coverage | -3718.31 | — | — | -4405.20 | -3289.00 | -2030.33 | -11743.50 | — | — | -28.61 | -30.01 | -17.16 | -14.32 | -13.45 | -13.83 | -16.46 | -27.73 | -60.35 | -73.62 | -8.56 | -14.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LAB stock.
Standard BioTools Inc.'s current P/E is -3.7x. The average P/E over the last 1 quarters is 6.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Standard BioTools Inc.'s current operating margin is -109.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Standard BioTools Inc.'s business trajectory between earnings reports.